Lacosamide Genepharm

Lacosamide, the active ingredient in Lacosamide Genepharm, is an anti‑epileptic presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Genepharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug used to manage seizure disorders.

Partial‑onset seizures: reduces seizure frequency in focal epilepsy. Focal epilepsy (add‑on therapy): improves seizure control when combined with other antiepileptics. Adjunctive treatment in epilepsy: helps patients who remain uncontrolled on existing regimens.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient light‑headed sensation. - Nausea: mild gastrointestinal upset. - Headache: occasional tension‑type pain. - Fatigue: feeling of reduced energy. - Blurred vision: temporary visual disturbance. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: emergence of depressive thoughts. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests. - Respiratory depression: especially with CNS depressants. - Anaphylaxis: rare hypersensitivity reaction.

When prescribing Lacosamide, consider the following safety measures.

Renal impairment: adjust dose and monitor renal function. Hepatic impairment: use caution and monitor liver enzymes. Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. Pregnancy: risk unknown; discuss benefits and risks with the prescriber. Concomitant CNS depressants: may increase sedation and dizziness. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lacosamide can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Class I antiarrhythmics: may exacerbate PR‑interval prolongation. - Carbamazepine: can reduce lacosamide plasma concentrations. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure.

Moderate Interactions (Monitor Closely): - Other antiepileptics: additive CNS depression possible. - Alcohol: may enhance dizziness and drowsiness. - Warfarin: monitor INR for potential anticoagulant effect changes.